Quinidine for ventricular arrhythmias: value of electrophysiologic testing.
Quinidine was evaluated during serial electrophysiologic testing with programmed ventricular stimulation in 89 patients with life-threatening ventricular arrhythmias. In 30 of the 89 patients, quinidine therapy prevented the initiation of ventricular tachycardia (VT) during programmed ventricular stimulation. In 8 additional patients no single drug tested was effective, and quinidine in combination with either mexiletine (7 patients) or propranolol (1 patient) prevented the initiation of VT during electrophysiologic testing. The mean serum concentrations of quinidine in the patients who responded and those who failed to respond were 2.9 +/- 0.8 and 2.8 +/- 1.1 micrograms/ml, respectively; however, but nonresponders were characterized by more severe congestive heart failure and an increased incidence of digitalis use. During chronic therapy (24 +/- 3 months) with quinidine either alone or in combination with a second antiarrhythmic drug in the 38 patients whose arrhythmia had been suppressed during electrophysiologic testing, 32 (84%) remain symptom-free while 3 have had recurrent arrhythmia and 3 discontinued quinidine because of adverse effects. These data demonstrate that quinidine, when selected on the basis of electrophysiologic testing, provides effective long-term prophylaxis against recurrent ventricular arrhythmia and that approximately 40% of patients tested are likely to respond either to quinidine alone or quinidine in combination with another antiarrhythmic agent.